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BACKGROUND: Triamterene, because of its potassium-
sparing properties, is frequently used in combinationwith
hydrochlorothiazide (HCTZ) to treat patients with hyper-
tension. By inhibiting the epithelial sodium channel
(ENaC) in the cortical collecting duct, triamterene reduces
potassium secretion, thus reducing the risk of hypokale-
mia. Whether triamterene has an independent effect on
blood pressure (BP) has not been well studied.
OBJECTIVE: To determine if triamterene provides an ef-
fect to further lower BP in patients treated with HCTZ.
DESIGN: We conducted an observational study using
electronic medical record data from the Indiana Network
for Patient Care. Participants were 17,291 patients with
the diagnosis of hypertension between 2004 and 2012.
MAIN MEASURES: BP was the primary outcome. We
compared the BP between patients who were taking
HCTZ, with and without triamterene, either alone or in
combination with other antihypertensive medications, by
using a propensity score analysis. For each medication
combination, we estimated the propensity score (i.e.,
probability) of a patient receiving triamterene using a lo-
gistic regression model. Patients with similar propensity
scores were stratified into subclasses and BP was com-
pared between those taking triamterene or not within
each subclass; the effect of triamterenewas then assessed
by combining BP differences estimated from all
subclasses.
KEY RESULTS: The mean systolic BP in the triamterene
+HCTZ groupwas 3.8mmHg lower than in theHCTZ only
group (p<0.0001); systolic BP was similarly lower for
patients taking triamterene with other medication combi-
nations. Systolic BP reduction was consistently observed
for different medication combinations. The range of sys-
tolic BP reduction was between 1 and 4 mm Hg, depend-
ing on the concurrently used medications.
CONCLUSIONS: In the present study, triamterene was
found to enhance the effect of HCTZ to lower BP. In addi-
tion to its potassium-sparing action, triamterene’s ability
to lower BP should also be considered.
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INTRODUCTION
Diuretics are widely used for treatment of hypertension.1,2 In
some individuals, diuretic-induced kaliuresis can result in
hypokalemia and lead to cardiac disturbances and metabolic
consequences.3–5 Hypokalemia is usually treated or prevented
by combining the diuretic with an inhibitor of the epithelial
sodium channel (ENaC),6,7 a membrane-bound ion channel
that promotes sodium uptake and potassium secretion. In
clinical practice, typical treatments include mineralocorticoid
receptor (MR) antagonists that reduce potassium excretion by
blocking aldosterone’s upregulation of ENaC, or direct ENaC
inhibitors such as amiloride and triamterene. The MR antag-
onists and the direct inhibitors of ENaC are referred to as
potassium-sparing diuretics.
Triamterene is a commonly prescribed potassium-sparing
diuretic.8 Unlike amiloride and the aldosterone antagonists,
whose respective antihypertensive properties have been well
documented,9,10 the BP-lowering effect of triamterene has not
been as clearly determined. In the few published studies of
triamterene, it failed to show a consistent effect on BP beyond
marginal reductions when high doses were used.11,12. A recent
Cochrane Review of six studies,13 including two efficacy trials
of triamterene with fewer than 150 patients each,14,15 reported
no significant BP effects of triamterene.
There is, however, reason to believe that triamterene, as an
ENaC inhibitor, should lower BP. ENaC is thought to play a
critical role in BP regulation.16 The level of ENaC activity is
reciprocally linked to the state of sodium retention through
aldosterone, and thus it can adjust to requirements for sodium.
Residing in the distal nephron, ENaC is also anatomically
positioned to make final adjustments to sodium balance.
Nonetheless, the clinical decision to use triamterene is almost
always based on its potassium-sparing properties and not on
its potential to affect BP.
By examining data from a large patient population, we
sought to determine whether hydrochlorothiazide (HCTZ)
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combined with triamterene was associated with a lower BP
than when HCTZ was used alone.
METHOD
Subjects
The study used clinical data from the Indiana Network for
Patient Care (INPC), an electronic clinical information ex-
change formerly known as the Regenstrief Medical Record
System (RMRS), which serves residents of metropolitan Indi-
anapolis and surrounding counties.17,18 We searched clinical
records in the INPC to identify individuals with the diagnosis
of hypertension and then extracted BP measures and prescrip-
tion records to determine the patients’ medication use. All
patient identifiers were removed before analysis. The Indiana
University Institutional Review Board approved the study.
Hypertension cases were identified based on ICD9 code
401.9 (unspecified essential hypertension), 401.1 (benign es-
sential hypertension), 401.0 (malignant essential hyperten-
sion), 255.10 (hyperaldosteronism, unspecified), 405.0 (ma-
lignant secondary hypertension), and 405.9 (unspecified sec-
ondary hypertension). Previous studies showed that ICD9
code had high specificity (~95 %) and positive predictive
value (~97 %) in identifying hypertension cases.19 Following
the Health Insurance Portability and Accountability Act of
1996 (HIPPA) against disclosure of dates of clinical visits,
we used the date of the first recorded hypertension diagnosis in
a given patient as an index date for that individual; dates of all
subsequent clinical visits and medication prescriptions by the
patient were coded as days from the index date. This coding
system allowed us to determine the time sequence of hyper-
tension treatment and BP measurement without revealing the
actual clinical visit and prescription dates.
Patient Characteristics
We obtained the clinical records from identified hypertension
cases between 2004 and 2012. Specifically, we extracted
relevant demographic and clinical information including age,
sex, race, and major comorbidities (using recorded ICD9
codes), including diabetes mellitus, chronic kidney disease,
coronary artery disease, myocardial infarction, congestive
heart failure, atrial fibrillation, hyperlipidemia, stroke, chronic
obstructive pulmonary disease, and depression. BP measures
in the patient medical records were also extracted for analysis.
Prescription Data
INPC receives medication dispensing data from Surescripts®,
a nationwide pharmacy claim network that connects pharma-
cies, payers, hospitals, physicians, and health information
exchanges.20 All prescription medications were identified by
the National Drug Code (NDC), a unique product identifier
used in the United States for drugs intended for human use.We
used the Medi-Span® software to classify the extracted NDC
code into specific classes of medications (Medi-Span. Master
Drug Data Base Documentation Manual. Indianapolis, IN:
Medi-Span; 2007.)
Classes of drugs that were deemed relevant to hypertensive
treatments were reviewed, categorized and considered in the
current analysis, including thiazide diuretics, loop diuretics,
adrenergic antagonists, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARBs), calcium
channel blockers (CCBs), and direct vasodilators. Inhibitors
of ENaC other than triamterene, such as spironolactone and
eplerenone, were excluded in the analysis. Combination drugs
were counted as multiple drugs. For example, Maxzide-25 ™
(triamterene/HCTZ) was counted as two individual drugs:
37.5 mg triamterene and 25 mg HCTZ.
We also compared the prescription orders as well as the
pharmacy dispensing records, when both were available, to
verify the dose prescribed and dispensed amount. In our study,
most of the patients received care at Eskenazi Health (formerly
Wishard Health), which dispensed HCTZ and triamterene in
50 mg and 75 mg tablets, respectively. Patients who received
HCTZ 50 mg and triamterene 75 mg were instructed to cut the
pills in half before consumption.
Analysis
We first evaluated the numbers of patients on different
drugs or drug combinations. We compared BP in
patients prescribed the same drugs with and without
triamterene. For example, we compared the BP in
patients prescribed HCTZ alone with the BP in those
patients prescribed HCTZ plus triamterene. Similarly, the
BP in patients prescribed an ACE inhibitor and a beta-
blocker were compared with the BP in those prescribed
the same classes of drugs plus triamterene. We chose to
compare the BP in matched drug groups to alleviate the
potential confounding effects of different antihyperten-
sive agents. For example, we did not compare patients
prescribed HCTZ and triamterene with those prescribed
HCTZ and an ACE inhibitor. Such a drug-specific ana-
lytical strategy limited the sample sizes in each compar-
ison. As a result, we were able to determine the BP
effects of triamterene in only a few commonly encountered
drug classes.
A challenge in analyzing the observed clinical records
was the lack of random drug assignment. The lack of
treatment randomization makes it difficult to causally
attribute the observed BP differences to triamterene. To
remedy this, we performed a propensity score analysis,
which is a commonly accepted approach for alleviating
confounding effects in observational studies; this method
has been used frequently in pharmacoepidemiologic re-
search.21,22 Propensity score analysis is based on the
premise that unbiased treatment effect estimates can be
achieved by comparing patients with similar propensity
of receiving a particular treatment.23 Therefore, by
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estimating the probabilities of individual patients receiv-
ing the treatment (i.e., propensity scores), and then
stratifying patients into subclasses based on the estimat-
ed propensity scores, one creates comparable groups
from which unbiased treatment effects can be estimated.
Final estimation is ascertained by combining estimates
from all subclasses using a weighted average formula.24
In this research, for each drug or drug combination, we
used a logistic regression model to estimate each
patient’s propensity score, i.e., the probability of being
prescribed triamterene. The logistic regression models
included all patient characteristics listed in Table 1. We
then stratified patients based on their estimated propen-
sity scores; patients with similar propensity scores were
put into the same subclass and BP was compared be-
tween those prescribed triamterene and those not pre-
scribed triamterene. Following the generally accepted
practice of propensity score analysis, we divided the
patients into propensity score quartiles, i.e., four sub-
classes. Triamterene effects on BP were first determined
within each subclass and then combined into an overall
treatment effect estimate. All subjects with BP assess-
ments were included in the analysis. To ensure that the
propensity analysis resulted in comparable subclasses,
we carefully examined the patient characteristics and
the propensity score distributions within each subclass.
All intermediate results are presented in an appendix of
the Supplemental material. An alternative method for
assessing the effects of triamterene was to conduct re-
gression analysis adjusting for the effects of covariates.
We performed regression analysis for each of the drug
groups. The findings were consistent with those from
the propensity score analysis. We examined the
potassium levels before and after a patient received
triamterene.
RESULTS
We identified 17,291 patients prescribed HCTZ (or a combi-
nation including HCTZ), of whom 3131 patients were pre-
scribed triamterene. The median dose of HCTZ was 25 mg for
both treatment groups. The median dose of triamterene was
37.5 mg for the triamterene group.
Patient demographic and clinical characteristics were pre-
sented in Table 1. Briefly, patients prescribed triamterene were
more likely to be female (77 % vs. 65 %; p<0.0001), more
likely African-American (67 % vs. 57 %; p<0.0001), less
likely to have diabetes (29 % vs. 34 %; p<0.0001), coronary
artery disease (12 % vs. 14 %; p=0.0004), myocardial infarc-
tion (4 % vs. 5 %; p=0.01), heart failure (7 % vs. 9 %;
p<0.0001), stroke (4 % vs. 5 %; p=0.0118), and chronic
obstructive pulmonary disease (12 % vs 14 %; p=0.0014).
Because of the relatively large sample size, we detected sig-
nificant differences in comorbidities between the patients pre-
scribed and not prescribed triamterene. With the exception of
those with diabetes, the observed prevalence rates of these
comorbidities tended to be small, usually less than 2 %. In the
subsequent propensity score analysis, we took these differ-
ences into account for the propensity score.
The distributions of the estimated propensity scores in the
two treatment groups had sufficient overlap (see Appendix),
which ensured adequate numbers of patients in each subclass
for the estimation of within-subclass triamterene effects. The
balance of patient characteristics within each subclass was
examined andwithin-subclass treatment effects were obtained.
All intermediate results were included in the online Supple-
ment. For treatment effect estimates, we used all patients
available for each subclass; no patients were excluded in the
process of propensity score subclassification. Combined treat-
ment effects, i.e., the estimated triamterene effects on systolic
and diastolic BP for different drug combinations are reported
in Tables 2 and 3. Estimated triamterene effects for all major
drug class combinations are presented graphically in Figure 1.
For each of the comparators below, statistically significant
differences were found for systolic BP, but none were signif-
icant for diastolic BP.
HCTZ
We first compared BP in patients prescribed HCTZ, with and
without triamterene. For each subclass, we calculated the
mean differences in systolic and diastolic BP between patients
on HCTZ alone and those on HCTZ and triamterene. Aggre-
gating the results in the four propensity score subclasses, we
obtained a combined BP difference; mean systolic BP in
patients prescribed triamterene was 3.8 mmHg lower than that
in patients prescribed HCTZ alone (135.75 vs. 131.32 mmHg;
p<0.0001). The difference in diastolic BP did not reach the
Table 1. Demographic and Clinical Characteristics of the Study
Subjects
Patient characteristics Without
triamterene
With
triamterene
p values
N=14,160 N=3131
Age at first recorded
hypertension
diagnosis
50.7±13.4 50.8±12.8 0.8282
Female 9253 (65.3 %) 2405 (76.8 %) < 0.0001
Black race 8107 (57.3 %) 2085 (66.6 %) < 0.0001
Diabetes 4709 (33.3 %) 892 (28.5 %) < 0.0001
Chronic kidney disease 1188 (8.4 %) 250 (8 %) 0.4575
Coronary artery disease 2024 (14.3 %) 368 (11.8 %) 0.0002
Myocardial infarction 670 (4.7 %) 115 (3.7 %) 0.0100
Congestive heart failure 1316 (9.3 %) 214 (6.8 %) < 0.0001
Hyperlipidemia 5433 (38.4 %) 1230 (39.3 %) 0.3406
Atrial fibrillation 567 (4 %) 116 (3.7 %) 0.4364
Stroke 641 (4.5 %) 110 (3.5 %) 0.0118
Chronic obstructive
pulmonary disease
1940 (13.7 %) 362 (11.6 %) 0.0014
Depression 3184 (22.5 %) 697 (22.3 %) 0.7852
Years since first
hypertension
treatment
3.3±4.2 3.1±4.1 0.0720
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level of statistical significance (81.27 vs. 79.74 mmHg;
p=0.1029). The BP differences are shown graphically in
Figure 1.
To verify our findings, we used regression analyses to
assess the triamterene effect by adjusting for the patient char-
acteristics, and by adjusting propensity scores. Both analyses
showed significantly lower systolic BP in patients prescribed
HCTZ and triamterene, as compared to patients prescribed
HCTZ alone. The mean magnitude of BP reduction was about
3.8 mmHg (SD 0.70 mmHg, p<0.0001), after adjusting for the
effects of patient demographics and major comorbidities.
HCTZ + ACE inhibitor
There were 1870 patients who were prescribed HCTZ + ACE
inhibitor and 255 who were prescribed the same classes of
medications and triamterene. We used a logistic regression
model to estimate the propensity for individual patients to be
prescribed triamterene. Stratifying the patients based on their
propensity scores, we calculated the mean systolic and dia-
stolic BP in each subclass. Combining the treatment effects
from all subclasses, we noted that the mean systolic BP was
2.4 mmHg lower in those taking triamterene (SD 1.15 mmHg,
p=0.0365). Regression analysis adjusting for patient character-
istics confirmed this finding (beta=2.2, SD=0.94, p=0.0213).
HCTZ + ACE inhibitor + CCB
We identified 1175 patients who were prescribed HCTZ, an
ACE inhibitor, and a CCB; 239 patients were prescribed the
same drugs plus triamterene. Using a propensity score sub-
classification, we first analyzed the BP differences within the
subclasses, and then combined treatment effect estimates for
an overall effect of triamterene. The mean systolic BP in the
triamterene group was 3.0 mmHg lower (SD 0.979 mmHg,
p=0.0024).
HCTZ + ACE inhibitor + beta blocker + CCB
We identified 1229 patients who were prescribed HCTZ +
ACE inhibitor + BB + CCB and 270 were prescribed the same
classes of medications plus triamterene. Combining the treat-
ment effects estimated from the subclasses, we noted that the
mean systolic BP was 3.5 mmHg lower in patients prescribed
triamterene (SD 1.2 mmHg, p=0.0039). Regression analysis
adjusting for patient characteristics confirmed this finding
(beta=3.155, SD=1.0103, p=0.0018).
HCTZ + all other medications
There were numerous combinations of antihypertensive med-
ications used concurrently with HCTZ. However, the numbers
of patients within each of these drug combinations tended to
be small. To analyze, we included all of the patients prescribed
those combinations in this analysis. In total, we identified
8019 patients who were prescribed HCTZ and some other
combinations of antihypertensives, and 1869 patients who
were prescribed the same classes of medications and triamter-
ene. Analysis showed that systolic BP was on average
1.1 mmHg lower in those taking triamterene (SD 0.39 mmHg;
p=0.0050).
Finally, we examined the plasma levels of potassium in
study patients when available. The overall potassium levels
between the two groups were identical (4.2 mmol/L). For
patients who were prescribed triamterene, we examined their
potassium levels before and after the initiation of triamterene.
Table 2. Estimated Effects of Triamterene on Systolic BP by Drug Class: Hydrochlorothiazide (HCTZ), Angiotensin-converting enzyme (ACE)
inhibitor, Beta-blocker (BB), Calcium channel blocker (CCB)
Drug combinations Number of patients
who did not receive
triamterene
Mean SBP of
patients who did
not receive
triamterene (SD)
Number of
patients who
received
triamterene
Mean SBP of
patients who
received
triamterene (SD)
Estimated effect
on systolic BP
from propensity
score analysis (SD)
p value
HCTZ 1865 135.75 (14.40) 498 131.32 (13.65) 3.80 (0.70) < 0.0001
HCTZ + ACE 1867 136.11 (14.61) 255 132.91 (13.29) 2.40 (1.15) 0.0365
HCTZ + ACE + CCB 1174 142.24 (15.54) 239 138.50 (13.66) 2.97 (0.98) 0.0024
HCTZ + ACE + BB + CCB 1228 143.15 (15.71) 270 140.07 (14.04) 3.50 (1.22) 0.0039
All drug combinations 14,147 139.02 (15.23) 3131 136.91 (14.69) 1.84 (0.29) < 0.0001
Table 3. Estimated Effects of Triamterene on Diastolic BP by Drug Class: Hydrochlorothiazide (HCTZ), Angiotensin-converting Enzyme
(ACE) Inhibitor, Beta-blocker (BB), Calcium Channel Blocker (CCB)
Drug combinations Number of patients
who did not receive
triamterene
Mean DBP of
patients who did
not receive
triamterene (SD)
Number of
patients who
received
triamterene
Mean DBP of
patients who
received
triamterene (SD)
Estimated effect
on diastolic BP
from propensity
score analysis (SD)
p value
HCTZ 1867 81.27 (10.13) 498 79.74 (9.47) 0.90 (0.55) 0.1029
HCTZ + ACE 1870 79.57 (10.51) 255 79.06 (9.62) 0.002 (0.94) 0.9981
HCTZ + ACE + CCB 1174 81.95 (11.05) 239 80.75 (9.72) 0.87 (1.09) 0.4248
HCTZ + ACE + BB + CCB 1229 80.94 (11.25) 270 80.26 (10.42) 1.20 (0.71) 0.0914
All drug combinations 14,159 80.18 (10.82) 3131 80.11 (10.18) 0.06 (0.20) 0.7733
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In our study data, potassium levels increased after patients
were put on triamterene, but the increase was small
(0.03 mmol/L) and not statistically significant (p=0.16).
DISCUSSION
In our study, triamterene used in combination with HCTZ,
presumably prescribed for its potassium-sparing properties,
was found to provide an added BP-lowering effect. We found
that systolic BP was 3.8 mm Hg lower in those who were
treated with HCTZ and triamterene as opposed to those treated
with HCTZ alone. When all drug combinations are consid-
ered, the difference was 1.8 mm Hg. Effects of such magni-
tude, although modest, are not drastically dissimilar to the
observed systolic BP effects of ACE inhibitors, (3–6 mm
Hg),25,26 calcium channel blockers (5 mm Hg),27 beta-
adrenergic blockers (3.8-4 mm Hg),28,29 when they were
compared against placebo controls. Importantly, these
reported differences were further reduced when these drugs
were compared against other antihypertensive agents.30–32
Viewed within this context, the magnitude of BP reduction
associated with the addition of triamterene was certainly not
trivial. This difference was also comparable to what was
observed when sodium intake was reduced from high to
intermediate levels in the Dietary Approaches to Stop Hyper-
tension (DASH) trial.33 When considered in population-scale
proportions, such an effect on BP would be expected to
produce a substantial reduction in cardiovascular morbidity,34
as well as the benefits derived from less frequent hypokalemia.
It may have, for example, contributed to the previously
reported reduction in cardiovascular-related mortality,
including sudden death in elderly hypertensive patients treated
with ENaC inhibitors.35 The findings of the present study
would appear to generate an additional rationale for consider-
ing the inclusion of triamterene in the treatment of
hypertension.
Data from randomized clinical trials evaluating the BP
effects of low doses of triamterene as monotherapy in patients
with hypertension have not been forthcoming. A recent
Cochrane Collaboration study reported little evidence that
triamterene, or for that matter, amiloride, affected BP.8 Inter-
estingly, among the trials reviewed by the Cochrane report
were two randomized trials of triamterene 50 mg plus chlor-
thalidone 25 mg or 50 mg, with 129 and 141 patients, respec-
tively.14,15 Neither study found significant BP benefit associ-
ated with the addition of triamterene. Conversely, our study
found a significant, albeit modest, reduction in BP with the
addition of triamterene at a lower dose, and the effect was
consistent across several major drug classes. The difference in
findings may be due to the much larger sample size we were
able to analyze in this study. Considering the large variability
of BP, it is difficult for studies with small sample sizes to find
moderate differences in BP. However, small studies using
triamterene at much higher doses (100–400 mg per day) did
show that triamterene had mild antihypertensive properties in
comparison to HCTZ or chlorthalidone.8,11,12,36,37 Consistent
with the current findings, a previous study reported that the
addition of amiloride lowered systolic BP significantly in
African Americans with uncontrolled low-renin hypertension
treated with either HCTZ or furosemide and a calcium channel
blocker9. Differences in the doses of drugs, severity of hyper-
tension, and race may have contributed to the variable con-
clusions as to the BP effects of triamterene.
Figure 1. Mean systolic and diastolic BP, and corresponding 95 % confidence intervals of mean BP in patients treated with and without
triamterene. BP differences between those who received and those who did not receive estimated triamterene were obtained from propensity
score analysis. Data are shown by drug class.
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Although triamterene lowered BP, purportedly by decreas-
ing sodium reabsorption, there may be an effect of increasing
serum potassium levels on BP.8 ENaC inhibitors, upon reach-
ing the cortical collecting duct, act directly on the channel to
affect the transport of sodium. The available direct inhibitors,
triamterene and amiloride, have been shown to reduce the
activity of ENaC by raising potassium levels. In the current
study, only a fraction of the patients had sequential serum
potassium measurements that could be used to examine the
sequential changes in potassium levels associated with triam-
terene. In the subset of patients with longitudinal serum po-
tassium measurements, we did observe a slight increase in
potassium levels after patients were put on triamterene. How-
ever, the inherent limitations of medical record data did not
permit us to adequately assess the long-term clinical conse-
quences of potassium-sparing effects of triamterene.
Another limitation of the current report was that the findings
were derived from observational data and not from a random-
ized trial. Considering the differences in patient characteris-
tics, propensity score analysis is unlikely to completely re-
move the various confounding effects. Additionally, the pro-
pensity score method does not guarantee a causal interpreta-
tion, especially when there are unmeasured or imperfectly
measured confounders. Nonetheless, the consistency of the
results across comparator groups gives more credence to the
BP-lowering effect of triamterene. Although we do not know
with certainty why triamterene was prescribed in a given
individual, it is not illogical to assume that the great majority
of the prescriptions were made for triamterene’s potassium-
sparing actions. Serum potassium levels were similar in the
two groups and not, as one might anticipate, higher in those
who also received triamterene. One explanation is that HCTZ-
treated patients who developed hypokalemia would in all
likelihood be given triamterene more often than HCTZ-
treated patients who did not develop hypokalemia. Other
limitations include lack of information on the timing of the
benefits, potential risk exposure misclassification, and un-
known generalizability of the study findings.
Notwithstanding these limitations, this may be the first
large-scale study that provides observationally derived evi-
dence that triamterene at the commonly prescribed dose of
37.5 mgwas associated with a lower systolic BP in individuals
with hypertension. The likelihood of a superior antihyperten-
sive response to the combination of triamterene with HCTZ
should be considered when selecting diuretics for the treat-
ment of hypertension.
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